Aytu BioScience to Present at Two Upcoming Investor Conferences

ENGLEWOOD, Colo., Nov. 30, 2015 /CNW/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, will present at two upcoming investor conferences. Aytu is scheduled to present live at VirtualInvestorConferences.com, an interactive real-time virtual conference, to be held December 3, 2015, and at LD Micro's Main Event Investor Conference, to be held December 2nd & 3rd, 2015 in Los Angeles and streamed live via webcast.

Josh Disbrow, Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend LD Micro's Main Event Investor Forum.


LD Micro's Main Event Investor Conference


Wednesday, December 2, 2015


8:30 am (Pacific Time) 


Luxe Sunset Bel Air, Los Angeles, CA






Thursday, December 3, 2015 


11:30 am (Eastern Time) 



The VirtualInvestorConferences.com presentation will be webcast live and remain available for an additional 90 days following the live presentation. To access the webcast, please visit the Investors section of the Aytu website at www.aytubio.com.

About Aytu BioScience, Inc.

Aytu BioScience, Inc. is a commercial-stage specialty healthcare company focused on urological and related conditions. The Company's products includes FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody that targets Prostate Specific Membrane Antigen (PSMA), a protein highly expressed by prostate cancer; as well as Primsol® (trimethoprim oral solution), the only FDA-approved oral solution of trimethoprim, the standard therapy for urinary tract infections.  Aytu's strategy is to continue building its portfolio of revenue-generating urology products and late-stage development assets, leveraging its commercial team and expertise to further build those brands within well-established markets.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc. Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. These risks are not exhaustive. Other sections of Aytu BioScience, Inc. Annual Report on Form 10-K and such other filed reports and documents include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.

Logo - http://photos.prnewswire.com/prnh/20151130/291566LOGO 


SOURCE Aytu BioScience, Inc.

For further information: For Investors & Media: Tiberend Strategic Advisors, Inc., Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664, Janine McCargo: jmccargo@tiberend.com; (646) 604-5150, http://www.aytubio.com

Organization Profile

Aytu BioScience, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890